Diffuse large B-cell lymphoma.

[1]  K. Young,et al.  EBV-positive diffuse large B-cell lymphoma of the elderly. , 2013, Blood.

[2]  A. Rosenwald,et al.  Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). , 2012, The Lancet. Oncology.

[3]  A. Nagler,et al.  A randomized study comparing yttrium‐90 ibritumomab tiuxetan (Zevalin) and high‐dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma , 2012, Cancer.

[4]  Y. Koh,et al.  Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas , 2012, Korean journal of pathology.

[5]  M. Routbort,et al.  Prognostic value of MYC rearrangement in cases of B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma , 2012, Cancer.

[6]  S. Ferrero,et al.  Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. , 2012, Blood.

[7]  J. Leonard,et al.  Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma , 2012, Leukemia & lymphoma.

[8]  M. Czuczman,et al.  Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype , 2011, Cancer.

[9]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[10]  A. Renand,et al.  IL-17-producing invariant NKT cells in lymphoid organs are recent thymic emigrants identified by neuropilin-1 expression. , 2011, Blood.

[11]  A. Ferreri.  How I treat primary CNS lymphoma. , 2011, Blood.

[12]  Dirk Hasenclever,et al.  Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. , 2011, Blood.

[13]  U. Surti,et al.  EBV-Positive Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue in the Posttransplant Setting: A Distinct Type of Posttransplant Lymphoproliferative Disorder? , 2011, The American journal of surgical pathology.

[14]  N. Schmitz,et al.  Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Friedberg,et al.  Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Hainsworth,et al.  Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Radford,et al.  R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Baeuerle,et al.  Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. , 2011, Experimental cell research.

[19]  Bruce D Cheson,et al.  Role of functional imaging in the management of lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Illidge,et al.  Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. , 2011, Blood.

[21]  A. Ho,et al.  Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Andrew Homb,et al.  18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.

[23]  Peter Martin,et al.  Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Kai Fu,et al.  Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[26]  T. Habermann,et al.  A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma , 2010, Leukemia.

[27]  Michael Hummel,et al.  Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. , 2010, Blood.

[28]  A. Rosenwald,et al.  Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study , 2010 .

[29]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[30]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Christine F. Wogan,et al.  Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Hammerman,et al.  Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2010, Cancer.

[33]  S. Pileri,et al.  Chronic inflammation, including autoimmunity, and lymphomagenesis , 2010 .

[34]  D. Rossi,et al.  Immunodeficiency, inherited and acquired and lymphomagenesis , 2010 .

[35]  N. Dang,et al.  Inotuzumab ozogamicin as novel therapy in lymphomas , 2010, Expert opinion on biological therapy.

[36]  Dirk Hasenclever,et al.  Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  E. Jaffe,et al.  T-cell/histiocyte-rich large B-cell lymphoma , 2010, Haematologica.

[38]  A. Sohani,et al.  Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  B. Coiffier,et al.  Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  T. Molina,et al.  R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study , 2009 .

[41]  Kai Fu,et al.  A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy , 2009, Clinical Cancer Research.

[42]  A. Levis,et al.  Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study , 2009, Haematologica.

[43]  L. Staudt,et al.  Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. , 2009, Blood.

[44]  J. Vose,et al.  Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[46]  N. Schmitz,et al.  CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2009, Blood.

[47]  B. Cheson.  The case against heavy PETing. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. Rahmouni,et al.  Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy , 2009, Journal of Nuclear Medicine.

[49]  S. Mackinnon,et al.  Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  C. Gisselbrecht.  Use of rituximab in diffuse large B‐cell lymphoma in the salvage setting , 2008, British journal of haematology.

[51]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[52]  J. Vose,et al.  Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003) , 2008 .

[53]  I. Lossos,et al.  Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  W. Chan,et al.  Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  P. Gaulard,et al.  Primary mediastinal (thymic) large B-cell lymphoma , 2008 .

[56]  A. Younes.  Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: Clues but no clear answers , 2008, Autophagy.

[57]  U. Jaeger,et al.  Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. , 2008, The Lancet. Oncology.

[58]  A. Nagler,et al.  Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma , 2008, Bone Marrow Transplantation.

[59]  R. Gressin,et al.  Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome , 2008, Scandinavian journal of infectious diseases.

[60]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[61]  M. Trněný,et al.  Treatment of Diffuse Large B-Cell Lymphoma with Rituximab, Intensive Induction and High-Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial. , 2007 .

[62]  B. Cheson,et al.  The role of FDG-PET scans in patients with lymphoma. , 2007, Blood.

[63]  C. Gisselbrecht,et al.  The impact of pre‐ and post‐transplantation positron emission tomography using 18‐fluorodeoxyglucose on poor‐prognosis lymphoma patients undergoing autologous stem cell transplantation , 2007, Cancer.

[64]  C. Copie-Bergman,et al.  Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  E. Campo,et al.  Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  A. Ferreri,et al.  Primary diffuse large B-cell lymphoma of the stomach. , 2007, Critical reviews in oncology/hematology.

[67]  M. Boccadoro,et al.  Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) , 2007, Leukemia.

[68]  G. Schwarzer,et al.  High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. , 2007, Cancer treatment reviews.

[69]  J. Vose,et al.  Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Ruland,et al.  Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. , 2007, Blood.

[71]  A. Nagler,et al.  Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. , 2007, Experimental hematology.

[72]  R. Gascoyne,et al.  Clinical Trials and Observations , 2007 .

[73]  T. Molina,et al.  CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Armitage,et al.  Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation , 2007 .

[77]  E. Vellenga,et al.  Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. , 2006, Blood.

[78]  L. Kanz,et al.  Matched Unrelated Donor Stem Cell Transplantation for Patients with Diffuse Large Cell B Cell Lymphoma: A Retrospective Analysis of 118 Patients Registered through the European Group for Blood and Marrow Transplantation (EBMT). , 2006 .

[79]  J. Baars,et al.  Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. , 2006, International journal of radiation oncology, biology, physics.

[80]  R. Bouabdallah,et al.  A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma , 2006, Bone Marrow Transplantation.

[81]  N. Bahlis,et al.  Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. , 2006, Blood.

[82]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[83]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[84]  A. Rosenwald,et al.  Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma , 2006, Clinical Cancer Research.

[85]  N. Schmitz,et al.  Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. , 2006, Blood.

[86]  H. Hsu,et al.  Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  U. Bunworasate,et al.  Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma , 2006, Leukemia & lymphoma.

[88]  A. Olshen,et al.  Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. , 2005, Blood.

[89]  Emmanuel Itti,et al.  [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.

[90]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Y. Tanaka,et al.  Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan , 2005, Bone Marrow Transplantation.

[92]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  J. Chan,et al.  Metallic implant-associated lymphoma: a distinct subgroup of large B-cell lymphoma related to pyothorax-associated lymphoma? , 2005, The American journal of surgical pathology.

[94]  Dong-ge Liu,et al.  [T cell/histiocyte-rich large B cell lymphoma]. , 2005, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[95]  C. Casper,et al.  The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care , 2005, British journal of haematology.

[96]  T. Molina,et al.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.

[97]  K. Aozasa,et al.  Alterations of DNA damage-response genes ATM and ATR in pyothorax-associated lymphoma , 2005, Laboratory Investigation.

[98]  S. Horning,et al.  Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  C. Craddock,et al.  Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. , 2004, Blood.

[100]  Ryan T. Phan,et al.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells , 2004, Nature.

[101]  R. Fisher,et al.  The epidemiology of non-Hodgkin's lymphoma , 2004, Oncogene.

[102]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. , 2004, Blood.

[103]  A. Zelenetz,et al.  Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. , 2004, Blood.

[104]  C. Craddock,et al.  Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant (RIT) regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL) , 2004 .

[105]  Chung-Che Chang,et al.  Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma , 2004, American Journal of Surgical Pathology.

[106]  R. Gressin,et al.  Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. , 2004, The New England journal of medicine.

[107]  Ramón Bosch,et al.  Building an outcome predictor model for diffuse large B-cell lymphoma. , 2004, The American journal of pathology.

[108]  A. Avilés,et al.  Interferon Alpha 2b as Maintenance Therapy Improves Outcome In Follicular Lymphoma , 2004, Leukemia & lymphoma.

[109]  I. Ghobrial,et al.  An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. , 2003, The New England journal of medicine.

[110]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[111]  P. Venugopal,et al.  Lymphomatoid granulomatosis treated with rituximab and chemotherapy. , 2003, Clinical advances in hematology & oncology : H&O.

[112]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[113]  S. Fujita,et al.  Non-Hodgkin’s Lymphoma Developing in a Pacemaker Pocket , 2003, International journal of hematology.

[114]  S. Pileri,et al.  Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  N. Schmitz,et al.  An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation , 2003, Bone Marrow Transplantation.

[116]  N. Harris,et al.  BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[117]  S. Kvaløy,et al.  Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[118]  K. Ohshima,et al.  Senile EBV+ B-Cell Lymphoproliferative Disorders: A Clinicopathologic Study of 22 Patients , 2003, The American journal of surgical pathology.

[119]  N. Schmitz,et al.  Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. , 2002, Blood.

[120]  Wei Gu,et al.  Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.

[121]  K. Aozasa,et al.  Pyothorax-associated lymphoma: a review of 106 cases. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[123]  S. Kvaløy,et al.  Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[124]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[125]  W. Chan,et al.  Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  J. Manning,et al.  Epstein–Barr Virus-Positive B-Cell Lymphoproliferative Disorders Arising in Immunodeficient Patients Previously Treated With Fludarabine for Low-Grade B-Cell Neoplasms , 2002, The American journal of surgical pathology.

[127]  Takashi Akasaka,et al.  De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. , 2002, Blood.

[128]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[129]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[130]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  S. Tucker,et al.  Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. , 2000, International journal of radiation oncology, biology, physics.

[132]  H. Tilly,et al.  Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients , 2000 .

[133]  G. Ceresoli,et al.  Consolidation Radiotherapy to Bulky or Semibulky Lesions in the Management of Stage III–IV Diffuse Large B Cell Lymphomas , 2000, Oncology.

[134]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[135]  J. Blay,et al.  The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. , 1998, Blood.

[136]  J Hermans,et al.  Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.

[137]  A. Hagenbeek,et al.  Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[139]  L. Cavanna,et al.  Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[140]  Y. Tomita,et al.  Hepatitis C viral genome in a subset of primary hepatic lymphomas. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[141]  F. Negro,et al.  Extranodal lymphomas associated with hepatitis C virus infection. , 1998, American journal of clinical pathology.

[142]  M. Wolter,et al.  Frequent In activation of CDKN2A and Rare Mutation of TP53 in PCNSL , 1998, Brain pathology.

[143]  P. Mclaughlin,et al.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. , 1998, Blood.

[144]  A. Hagenbeek,et al.  For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[145]  S. Pileri,et al.  Pyothorax-associated lymphoma: description of the first two cases detected in Italy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[146]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[147]  D. Sansonno,et al.  Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. , 1997, Blood.

[148]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[149]  P. Pandolfi,et al.  The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation , 1997, Nature Genetics.

[150]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[151]  R S Chaganti,et al.  BCL8, a novel gene involved in translocations affecting band 15q11-13 in diffuse large-cell lymphoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[152]  A. Pileri,et al.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[153]  T. Lister,et al.  Role of image-guided core-needle biopsy in the management of patients with lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  E. Cesarman,et al.  Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. , 1996, Blood.

[155]  G. Gaidano,et al.  Molecular heterogeneity of B‐lineage diffuse large cell lymphoma , 1996, Genes, chromosomes & cancer.

[156]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[157]  R. Chaganti,et al.  Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. , 1995, The EMBO journal.

[158]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[159]  M. Ladanyi,et al.  Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. , 1994, The New England journal of medicine.

[160]  K Offit,et al.  Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. , 1993, Science.

[161]  M. Fukayama,et al.  Epstein-Barr virus in pyothorax-associated pleural lymphoma. , 1993, The American journal of pathology.

[162]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[163]  B. Coiffier,et al.  Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  P. Lindgren,et al.  Ultrasound Guided Tumour Biopsy in the Anterior Mediastinum , 1992, Acta radiologica.

[165]  K. Sullivan,et al.  Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  H. Lazarus,et al.  The Treatment of Progressive Non-Hodgkin's Lymphoma With Intensive Chemoradiotherapy and Autologous Marrow Transplantation , 1990 .

[167]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  M. Oken,et al.  bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. , 1989, The New England journal of medicine.

[169]  J. Armitage,et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.

[170]  Weisenburger Dd.  Lymphoid malignancies in Nebraska: a hypothesis. , 1985 .

[171]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[172]  L. Medeiros,et al.  B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma , 2013 .

[173]  L. Medeiros,et al.  Diffuse Large B-Cell Lymphoma, Not Otherwise Specified , 2013 .

[174]  M. Bissell.  Epstein-Barr virus–positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations , 2011 .

[175]  C. Rübe,et al.  Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[176]  K. Hoang-Xuan,et al.  A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. , 2006, Blood.

[177]  Enrica Morra,et al.  Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. , 2006, Haematologica.

[178]  R. Gascoyne,et al.  Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[179]  P. Zinzani,et al.  Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. , 2005, Haematologica.

[180]  A. Levis,et al.  High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. , 2005, Haematologica.

[181]  H. Ohno,et al.  Coexistent Rearrangements of c-MYC,BCL2, andBCL6 Genes in a Diffuse Large B-Cell Lymphoma , 2004, International journal of hematology.

[182]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[183]  T. Molina,et al.  Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[184]  F. Cavalli,et al.  Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  Emili Montserrat,et al.  Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.

[186]  C. Mayr,et al.  High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. , 2003, Haematologica.

[187]  L. Abrey,et al.  Central nervous system lymphoma. , 2002, Hematology. American Society of Hematology. Education Program.

[188]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[189]  G. Jerusalem,et al.  Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.

[190]  J. Diebold,et al.  Lymphomas associated with HIV infection. , 1997, Cancer surveys.

[191]  Vianna Nj.  The malignant lymphomas: epidemiology and related aspects. , 1977 .

[192]  T. Kinoshita,et al.  Age-related Ebv-associated B-cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: a Study of 96 Patients Clinical Oncology , 2022 .